Drug companies support parts of Trump’s plan to lower drug prices

Representatives from AbbVie, AstraZeneca, Bristol-Myers Squibb, Janssen Pharmaceuticals, Merck, Pfizer and Sanofi voiced support for drug rebate reform, value-based program creation, and increasing transparency, biologics and generics awareness to lower U.S. drug prices at a recent Senate Finance Committee hearing.
President Donald J. Trump has called for lower drug prices, and has included these steps among his proposals.
Under the current pricing structure, drug prices are higher because they are then offset by rebates to pharmacy benefit managers.
Senator Ron Wyman, D-Oregon, said this

Source link

Back to top button